At the time of writing, Cellebrite DI Ltd [CLBT] stock is trading at $22.52, up 5.78%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CLBT shares have gain 13.28% over the last week, with a monthly amount glided 18.53%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cellebrite DI Ltd [NASDAQ: CLBT] stock has seen the most recent analyst activity on March 28, 2024, when Needham reiterated its Buy rating and also boosted its price target to $13.50 from $13. Previously, William Blair upgraded its rating to Outperform on March 13, 2024. On February 16, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $12 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $11 on July 19, 2023. William Blair downgraded its rating to a Mkt Perform. BofA Securities downgraded its rating to Neutral for this stock on August 12, 2022, and downed its price target to $6. In a note dated February 24, 2022, JP Morgan initiated an Overweight rating and provided a target price of $10.50 on this stock.
For the past year, the stock price of Cellebrite DI Ltd fluctuated between $7.91 and $21.72. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Cellebrite DI Ltd [NASDAQ: CLBT] shares were valued at $22.52 at the most recent close of the market. An investor can expect a potential drop of -11.19% based on the average CLBT price forecast.
Analyzing the CLBT fundamentals
According to Cellebrite DI Ltd [NASDAQ:CLBT], the company’s sales were 385.17M for trailing twelve months, which represents an 26.94% jump. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.15%, Pretax Profit Margin comes in at -0.8%, and Net Profit Margin reading is -0.82%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -4.77 and Total Capital is 0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.51 points at the first support level, and at 20.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.08, and for the 2nd resistance point, it is at 23.64.
Ratios To Look Out For
It is important to note that Cellebrite DI Ltd [NASDAQ:CLBT] has a current ratio of 1.81. Further, the Quick Ratio stands at 1.78, while the Cash Ratio is 0.5. Considering the valuation of this stock, the price to sales ratio is 12.87, the price to book ratio is 15.71.
Transactions by insiders
Recent insider trading involved Aliazar Keinan, Director, that happened on Dec 11 ’24 when 19385.0 shares were purchased. Director, NADINE BAUDOT-TRAJTENBERG completed a deal on Dec 10 ’24 to buy 619.0 shares. Meanwhile, Director NADINE BAUDOT-TRAJTENBERG bought 35223.0 shares on Dec 09 ’24.
